Ipamorelin

Buy Ipamorelin: The Selective GH Secretagogue for Pituitary Research

Ready to buy Ipamorelin for your lab? Sino Research Peptide Manufacturer supplies high-purity Ipamorelin peptide, formulated specifically for laboratory and research use. Below, you’ll find a full research overview of this selective growth hormone secretagogue, along with everything you need to know before you buy Ipamorelin online.

What Is Ipamorelin Peptide?

Ipamorelin is a synthetic peptide composed of five amino acids (Aib-His-D-2-Nal-D-Phe-Lys-NH2), formally classified as a Growth Hormone Secretagogue (GHS). Its name reflects the intention behind its development: researchers designed Ipamorelin to act through ghrelin receptor binding.

The ghrelin receptors on the pituitary gland — the gland naturally involved with growth hormone (hGH) synthesis — are also known as Growth Hormone Secretagogue receptors (GHS-R). Through this mechanism, Ipamorelin may trigger the GHS-Rs on the pituitary gland and potentially stimulate growth hormone release.

A Highly Selective GHS

Ipamorelin stands out as the first synthetic GHS that appears highly selective, potentially augmenting hGH production without affecting other pituitary hormones such as prolactin or adrenocorticotropic hormone (ACTH). Consequently, the potential increase in hGH might promote lipolysis and insulin-like growth factor-1 (IGF-1) synthesis. Since IGF-1 may mediate hGH’s anabolic actions, the peptide may in turn support cellular proliferation and bone and muscle anabolism.

Chemical Makeup

Ipamorelin Peptide Benefits: What Does the Research Say?

Before you buy Ipamorelin online, it helps to understand what current research suggests about its potential applications. Below, we break down the key study areas.

Ipamorelin and Selective Agonism

A 1998 murine model-based study suggested that Ipamorelin may release growth hormone from pituitary cells. When researchers presented Ipamorelin to swine and pentobarbitone-anesthetized rats, it reportedly triggered growth hormone release. The researchers hypothesized that Ipamorelin acts as a growth receptor agonist, stimulating GH release through potential affinity for growth hormone receptors.

Notably, the researchers described Ipamorelin as the first GHS-R agonist with selectivity for GH release comparable to GHRH, calling it “a very interesting candidate for future clinical development.” Additional studies have suggested Ipamorelin may increase hGH secretion without significantly affecting other pituitary hormones, such as prolactin or ACTH.

Ipamorelin and Growth Hormone Synthesis

In vitro studies suggest Ipamorelin’s interaction with GHS receptors may affect somatotroph cells in the anterior pituitary gland by triggering cellular signaling events. This theorized pathway involves activation of phospholipase C (PLC), which some researchers believe may increase release of inositol triphosphate (IP3) and diacylglycerol (DAG). IP3 might then stimulate calcium ion (Ca2+) discharge from internal cell stores, while DAG might activate protein kinase C (PKC) — together potentially triggering exocytosis of growth-hormone-filled vesicles from pituitary cells.

In a late-1999 clinical trial, researchers presented Ipamorelin to eight test subjects every 15 minutes over a set period. Two hours later, growth hormone levels had apparently increased significantly, tending toward as much as 80mIU/l (roughly 26.6ng/ml) — an enhancement that appeared to exceed a 60-fold uplift compared to placebo baseline levels.

Ipamorelin and Bone Tissue

Researchers have theorized that Ipamorelin may positively influence bone mineral density by stimulating osteoblasts via hGH-mediated mechanisms, potentially enhancing their proliferation, growth, and specialization. In one study, murine models exposed to Ipamorelin or a placebo underwent real-time DEXA assessments at the femur and L6 vertebra, followed by pQCT scans of the femur bones.

Preliminary findings implied that Ipamorelin may have contributed to increased body mass and elevated tibial and vertebral bone mineral content (BMC) compared to placebo. The pQCT data suggested that this augmentation in cortical BMC may have stemmed from an enlargement in bone cross-sectional area, while cortical volumetric bone mineral density (BMD) appeared to remain steady.

Ipamorelin and Digestion

Researchers have also explored Ipamorelin’s potential role in gastric emptying. In one study, scientists surgically decelerated gastric emptying in murine models, then measured how much a marked substance lingered in the stomach 15 minutes after intragastric introduction. Ipamorelin appeared to markedly accelerate the emptying process compared to controls.

Further research examined the compound’s effect on gastric smooth muscle contractility, activated by acetylcholine and electrical field stimulation. When researchers studied Ipamorelin and ghrelin together, decelerated peristalsis appeared to be mitigated — suggesting Ipamorelin may enhance gastric smooth muscle contractility.

Ipamorelin and Appetite

Ipamorelin’s potential action on ghrelin receptors may enhance hunger signals and, in turn, contribute to body mass changes. Research suggests models exposed to Ipamorelin sustained an estimated 15% surge in body weight, with researchers speculating this may relate to a proportional increase in fat pad weight relative to total body weight.

DEXA scans in this research might indicate a comparative rise in body fat percentage. Researchers also speculate Ipamorelin might elevate serum leptin levels, a hormone considered crucial to energy balance and hunger regulation — prompting scientists to consider increased food consumption as a potential contributor to the weight gain noted in these models.

Ipamorelin and Nitrogen Balance

Researchers suggest Ipamorelin may mediate anabolic action, potentially linked to hGH and IGF-1 synthesis, which they’ve assessed through its impact on nitrogen balance. One investigation examined Ipamorelin’s action on liver markers associated with alpha-amino-nitrogen conversion during induced catabolic states, focusing on the liver’s capacity to synthesize urea-N (CUNS).

Findings suggested Ipamorelin might have contributed to a possible 20% reduction in CUNS compared to an artificially induced catabolic condition. It may also have diminished expression of urea cycle enzymes, possibly restoring nitrogen balance and altering nitrogen concentrations across different organs.

Where to Buy Ipamorelin Online

Ipamorelin: Where to Buy

If you’ve been asking “Ipamorelin, where to buy?”, Sino Research Peptide Manufacturer offers a straightforward, reliable path to research-grade material. Every batch ships with purity verification, so you always know exactly what you’re working with.

Buy Ipamorelin Peptide with Confidence

You can buy Ipamorelin peptide directly through our platform, with fast, tracked dispatch to laboratories and research institutions. Whether you’re placing your first order or restocking for an ongoing study, our streamlined process keeps your research moving.

Ipamorelin Peptide for Sale Online

We keep Ipamorelin peptide for sale online, manufactured under strict, controlled laboratory conditions for consistent, reproducible research results. If you’ve been wondering where to buy Ipamorelin, our team is ready to support your research timeline.

Important Research Notice

Ipamorelin peptide is available for research and laboratory purposes only. It is not intended for human or veterinary use. Please review and adhere to our Terms and Conditions before placing an order.

References:

1. K. Raun et al., Ipamorelin, the first selective growth hormone secretagogue, Endocrinology, November 1998.
2. Sinha DK, Balasubramanian A, Tatem AJ, Rivera-Mirabal J, Yu J, Kovac J, Pastuszak AW, Lipshultz LI. Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. Transl Androl Urol. 2020 Mar;9(Suppl 2):S149-S159. doi: 10.21037/tau.2019.11.30. PMID: 32257855; PMCID: PMC7108996 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7108996/
3. Jiménez-Reina, L., Cañete, R., de la Torre, M. J., & Bernal, G. (2002). Influence of chronic treatment with the growth hormone secretagogue Ipamorelin, in young female rats: somatotroph response in vitro. Histology and histopathology, 17(3), 707–714. https://doi.org/10.14670/HH-17.707
4. Gobburu, J.V.S., Agersø, H., Jusko, W.J. et al. Pharmacokinetic-Pharmacodynamic Modeling of Ipamorelin, a Growth Hormone Releasing Peptide, in Human Volunteers. Pharm Res 16, 1412–1416 (1999).
5. Svensson, J., Lall, S., Dickson, S. L., Bengtsson, B. A., Rømer, J., Ahnfelt-Rønne, I., Ohlsson, C., & Jansson, J. O. (2000). The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats. The Journal of endocrinology, 165(3), 569–577. https://doi.org/10.1677/joe.0.1650569
6. Greenwood-Van Meerveld, B., Tyler, K., Mohammadi, E., & Pietra, C. (2012). Efficacy of ipamorelin, a ghrelin mimetic, on gastric dysmotility in a rodent model of postoperative ileus. Journal of experimental pharmacology, 4, 149–155. https://doi.org/10.2147/JEP.S35396
7. Lall, S., Tung, L. Y., Ohlsson, C., Jansson, J. O., & Dickson, S. L. (2001). Growth hormone (GH)-independent stimulation of adiposity by GH secretagogues. Biochemical and biophysical research communications, 280(1), 132–138. https://doi.org/10.1006/bbrc.2000.4065
8. Aagaard, N. K., Grøfte, T., Greisen, J., Malmlöf, K., Johansen, P. B., Grønbaek, H., Ørskov, H., Tygstrup, N., & Vilstrup, H. (2009). Growth hormone and growth hormone secretagogue effects on nitrogen balance and urea synthesis in steroid treated rats. Growth hormone & IGF research: official journal of the Growth Hormone Research Society and the International IGF Research Society, 19(5), 426–431. https://doi.org/10.1016/j.ghir.2009.01.001